TY - JOUR
T1 - Clinical outcomes of patients with breast cancer in a phase i clinic
T2 - The M. D. Anderson cancer center experience
AU - Wheler, Jennifer
AU - Tsimberidou, Apostolia M.
AU - Moulder, Stacy
AU - Cristofanilli, Massimo
AU - Hong, David
AU - Naing, Aung
AU - Pathak, Raminder
AU - Liu, Suyu
AU - Feng, Lei
AU - Kurzrock, Razelle
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2010/2/1
Y1 - 2010/2/1
N2 - Purpose: Patients with metastatic breast cancer (MBC) refractory to standard therapy have a poor prognosis. We assessed prognostic factors and clinical outcomes for patients with MBC referred to a phase I clinic focused primarily on targeted agents. Patients and Methods: We reviewed the medical records of sequential patients with MBC who presented to our phase I clinic between September 2004 and May 2008 to assess baseline patient characteristics, overall survival (OS), and clinical benefit. Results: A total of 92 patients were identified, with a median age of 53 years (range, 28-83 years). The median number of previous therapies was 5 (range, 1-16 therapies). Of 92 patients, 78 were eligible for and offered ≥ 1 phase I clinical trial. With a median follow-up of 7.4 months, the median OS was 6.7 months (95% CI, 5.2-9.7). In multivariate analysis, independent factors predicting shorter survival were ≥ 10 previous treatments (vs. < 10 previous treatments; hazard ratio [HR], 3.27; 95% CI, 1.37-7.81; P = .008), Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2/3 (vs. 0/1; HR, 2.92; 95% CI, 1.28-6.66; P = .01), and albumin level < 3.5 g/dL (vs. > 3.5 g/dL; HR, 2.88; 95% CI, 1.41-5.89; P = .004). Conclusion: Patients with locally advanced or metastatic breast cancer referred for our phase I studies had a median survival of 6.7 months. Heavily pretreated disease, poor ECOG PS, and/or low albumin levels were associated with significantly shorter survival in a multivariate analysis.
AB - Purpose: Patients with metastatic breast cancer (MBC) refractory to standard therapy have a poor prognosis. We assessed prognostic factors and clinical outcomes for patients with MBC referred to a phase I clinic focused primarily on targeted agents. Patients and Methods: We reviewed the medical records of sequential patients with MBC who presented to our phase I clinic between September 2004 and May 2008 to assess baseline patient characteristics, overall survival (OS), and clinical benefit. Results: A total of 92 patients were identified, with a median age of 53 years (range, 28-83 years). The median number of previous therapies was 5 (range, 1-16 therapies). Of 92 patients, 78 were eligible for and offered ≥ 1 phase I clinical trial. With a median follow-up of 7.4 months, the median OS was 6.7 months (95% CI, 5.2-9.7). In multivariate analysis, independent factors predicting shorter survival were ≥ 10 previous treatments (vs. < 10 previous treatments; hazard ratio [HR], 3.27; 95% CI, 1.37-7.81; P = .008), Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2/3 (vs. 0/1; HR, 2.92; 95% CI, 1.28-6.66; P = .01), and albumin level < 3.5 g/dL (vs. > 3.5 g/dL; HR, 2.88; 95% CI, 1.41-5.89; P = .004). Conclusion: Patients with locally advanced or metastatic breast cancer referred for our phase I studies had a median survival of 6.7 months. Heavily pretreated disease, poor ECOG PS, and/or low albumin levels were associated with significantly shorter survival in a multivariate analysis.
KW - Absolute neutrophil count
KW - Albumin
KW - Outcome predictors
KW - Performance status
UR - http://www.scopus.com/inward/record.url?scp=76949107605&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=76949107605&partnerID=8YFLogxK
U2 - 10.3816/CBC.2010.n.006
DO - 10.3816/CBC.2010.n.006
M3 - Article
C2 - 20133258
AN - SCOPUS:76949107605
SN - 1526-8209
VL - 10
SP - 46
EP - 51
JO - Clinical breast cancer
JF - Clinical breast cancer
IS - 1
ER -